Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus

Obesity

Volumn 22, Issue 4, 2014, Pages 1042-1049

  Bays, Harold E ^a   Weinstein, Richard ^b   Law, Gordon ^c   Canovatchel, William ^c  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b Diablo Clinical Research   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CANAGLIFLOZIN; PLACEBO; ANTIOBESITY AGENT; GLUCOSE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLUCOSURIA; HEADACHE; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; INCONTINENCE; MALE; MICTURITION DISORDER; MULTICENTER STUDY; NAUSEA; NOCTURIA; OBESITY; OSMOTIC DIURESIS; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; POLYURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; STRESS INCONTINENCE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINAL PRURITUS; VAGINITIS; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; OVERWEIGHT; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; ANTI-OBESITY AGENTS; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE; GLUCOSIDES; HUMANS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; SODIUM-GLUCOSE TRANSPORT PROTEINS; THIOPHENES; TREATMENT OUTCOME;

EID: 84897447957     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20663     Document Type: Article

References (26)

1. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.
2. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013; 36: 2508-2515.
3. Stenlöf K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382.
4. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
5. Bays H,. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009; 25: 671-681.
6. Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE 2012; 7: e30555.
7. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669-672.
8. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539-545.
9. Polidori D, Sha S, Ghosh A, Plum-Morschel L, Heise T, Rothenberg P,. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: E867-E871.
10. Sarich T, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2), increases 24-h urinary glucose excretion and decreases body weight in obese subjects (Abstract). Diabetes 2010; 59.
11. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
12. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: developing products for weight management. 2007; 1-19.
13. National Cholesterol Education Program, National Heart LaBI, National Institutes of Health. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. 2002; 1-284.
14. Kolotkin RL, Crosby RD, Kosloski KD, Williams GR,. Development of a brief measure to assess quality of life in obesity. Obes Res 2001; 9: 102-111.
15. Kolotkin RL, Crosby RD,. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-Lite) in a community sample. Qual Life Res 2002; 11: 157-171.
16. Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K,. Efficacy and safety of canagliflozin in older subjects with type 2 diabetes: a randomized trial. Hosp Pract 2013; 41: 72-84.
17. Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950.
18. Toubro S, Cefalu WT, Xie J, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes (Abstract). Diabetologia 2012; 55: S313-S314.
19. Nyirjesy P, Zhao Y, Ways K, Usiskin K,. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012; 28: 1173-1178.
20. Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5: e197.
21. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR,. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009; 17: 494-503.
22. Van Gaal LF, Broom JI, Enzi G, Toplak H,. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998; 54: 125-132.
23. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722-733.
24. Zhou YH, Ma XQ, Wu C, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE 2012; 7: e39062.
25. Bays HE,. Adiposopathy: is "sick fat" a cardiovascular disease? J Am Coll Cardiol 2011; 57: 2461-2473.
26. Bays HE,. Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies. Am J Cardiol 2012; 110: 4B-12B.